Author

Koray Onuk

Observed names: K. Onuk, Onuk K, Onuk Koray, Onuk, Koray

Observed institution: AbbVie (United States)

ORCID: 0000-0002-8957-6537

Observed ORCID: 0000-0002-8957-6537

OpenAlex ID: A5040141336

Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach

2018 · Angelo Antonini, A. Jon Stoessl, et al. · Current Medical Research and Opinion · 282

PDF

Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

2017 · Angelo Antonini, Werner Poewe, et al. · Parkinsonism & Related Disorders · 220

PDF

Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients

2019 · Alfonso Fasano, Victor S. C. Fung, et al. · BMC Neurology · 127

PDF

Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications

2021 · Angelo Antonini, Per Odin, et al. · Parkinsonism & Related Disorders · 63

PDF

Application of the ‘5-2-1’ Screening Criteria in Advanced Parkinson’s Disease: Interim Analysis of DUOGLOBE

2020 · Jason Aldred, Marieta Anca-Herschkovitsch, et al. · Neurodegenerative Disease Management · 54

PDF

Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

2022 · Irene A. Malaty, Pablo Martinez-Martin, et al. · BMC Neurology · 47

PDF

An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients

2017 · Rejko Krüger, Paul Lingor, et al. · Advances in Therapy · 32

PDF

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel

2017 · Stephen Pedersen, Martin Suedmeyer, et al. · Journal of Multidisciplinary Healthcare · 24

PDF

Characterizing Advanced Parkinson’s Disease: Romanian Subanalysis from the OBSERVE-PD Study

2021 · Jozsef Attila Szasz, Dragos Catalin Jianu, et al. · Parkinson s Disease · 21

PDF

Criteria for identification of advanced Parkinson’s disease: the results of the Italian subgroup of OBSERVE-PD observational study

2022 · Alessandro Stefani, Alessandro Tessitore, et al. · BMC Neurology · 19

PDF

Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum: Revelations from the MANAGE-PD validation cohort

2023 · Hubert H. Fernandez, Per Odin, et al. · Parkinsonism & Related Disorders · 15

PDF

Characterization of advanced Parkinson’s disease in Germany: results of the non-interventional OBSERVE-PD study

2022 · David J. Pedrosa, Florin Gandor, et al. · Neurological Research and Practice · 14

PDF

Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries

2022 · Angelo Antonini, Rajesh Pahwa, et al. · Neurology and Therapy · 14

PDF

Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE‐PD observational study

2022 · Alfonso Fasano, Victor S. C. Fung, et al. · Acta Neurologica Scandinavica · 13

PDF

Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study

2020 · Andrew Evans, Victor S.C. Fung, et al. · Clinical Parkinsonism & Related Disorders · 11

PDF

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

2026 · K. Ray Chaudhuri, Bruno Bergmans, et al. · Movement Disorders Clinical Practice · 7

Characterisation of advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Swiss subgroup

2021 · J. Carsten Möller, Christian R. Baumann, et al. · Swiss Medical Weekly · 4

PDF

Az előrehaladott Parkinson-kór jellemzői a klinikai gyakorlatban: az OBSERVE-PD vizsgálat eredményei és a magyarországi alcsoport elemzése

2020 · Annamária Takáts, Zsuzsanna Aschermann, et al. · Ideggyógyászati Szemle · 4

MANAGE-PD: A clinician-reported tool to identify patients with Parkinson’s Disease inadequately controlled on oral medications – Results from vignette-based validation (P5.8-039)

2019 · Angelo Antonini, Per Odin, et al. · Neurology · 3

Evaluation of the Clinical Outcomes and Disease Burden in Advanced Parkinson’s Disease Patients: PROSPECT Study Preliminary Results (P10-11.009)

2023 · Alberto Espay, Pilar Sanchez Alonso, et al. · Neurology · 2

Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”

2024 · Angelo Antonini, K. Ray Chaudhuri, et al. · BMC Neurology · 1

PDF

‘Advanced’ Parkinson’s disease characteristics in clinical practice: results from the OBSERVE-PD study, a cross-sectional observational study of 2615 patients (P6.001)

2017 · Alfonso Fasano, Leonardo Lopiano, et al. · Neurology · 1

Impact of Uncontrolled Motor Fluctuations in Parkinson’s Disease: Real-World Insights from the PROSPECT Observational Study

2026 · Alberto J. Espay, Luc Defebvre, et al. · Advances in Therapy

PDF

Increased “Off” Time is Associated with Poorer Clinical and Humanistic Outcomes in Patients with Advancing Parkinson’s Disease: Results From the PROSPECT Observational Study (P5-16.013)

2026 · Pilar Sanchez Alonso, David Houghton, et al. · Neurology

20740. Datos De Vida Real Sobre La Evolución a Largo Plazo De La Carga De La Enfermedad De Parkinson Avanzada En La Muestra Española Del Estudio Observacional Internacional Prospect

2024 · O. de Fàbregues Nebot, M. Blázquez Estada, et al. · Neurology Perspectives

Works count: 43

Citation count: 978

H-index: 13

I10-index: 15